Phase I Open-Label Pharmacokinetics and Safety of Talazoparib

To investigate the effect of mild, moderate or severe hepatic impairment on the PK of talazoparib following daily oral dosing for 22 consecutive days, in patients with advanced solid tumors.

November 16, 2016